Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Arrowhead Pharmaceuticals by 8.4% during the 1st quarter, acquiring a total of 13,202,562 shares worth approximately $168 million.
• Other institutional investors have also raised their stakes, with 62.61% of the company's stock now held by institutional investors.
• Arrowhead Pharmaceuticals reported a loss of $1.26 EPS for the last quarter, falling short of analysts' estimates, with projected average EPS of -2.42 for the current fiscal year.

Vanguard Group Inc. boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 8.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,202,562 shares of the biotechnology company's stock after purchasing an additional 1,018,273 shares during the quarter. Vanguard Group Inc. owned about 9.61% of Arrowhead Pharmaceuticals worth $168,201,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Privium Fund Management B.V. increased its stake in Arrowhead Pharmaceuticals by 65.3% in the first quarter. Privium Fund Management B.V. now owns 629,214 shares of the biotechnology company's stock valued at $8,016,000 after purchasing an additional 248,628 shares during the period. XTX Topco Ltd acquired a new position in Arrowhead Pharmaceuticals in the 1st quarter valued at about $133,000. GSA Capital Partners LLP raised its stake in Arrowhead Pharmaceuticals by 514.4% during the 1st quarter. GSA Capital Partners LLP now owns 71,685 shares of the biotechnology company's stock valued at $913,000 after acquiring an additional 60,018 shares during the last quarter. Pinnacle Associates Ltd. acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth approximately $1,798,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth approximately $174,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 9,389 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $20.00, for a total transaction of $187,780.00. Following the completion of the sale, the insider directly owned 262,122 shares in the company, valued at approximately $5,242,440. This trade represents a 3.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ARWR shares. Royal Bank Of Canada dropped their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Finally, Citigroup dropped their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $43.14.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock traded up $0.58 during midday trading on Friday, reaching $21.33. The company's stock had a trading volume of 2,646,214 shares, compared to its average volume of 2,268,002. The firm has a market capitalization of $2.95 billion, a PE ratio of -16.66 and a beta of 0.94. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $27.34. The stock's 50 day simple moving average is $17.10 and its 200 day simple moving average is $15.93. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same period in the previous year, the company earned ($1.38) EPS. On average, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.